Abivax S.A.
23
2
4
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.7%
2 terminated/withdrawn out of 23 trials
88.9%
+2.4% vs industry average
13%
3 trials in Phase 3/4
50%
8 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (23)
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
Role: lead
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Role: lead
Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
Role: lead
Phase 1 Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation
Role: lead
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Role: lead
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
Role: lead
Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis
Role: lead
ABTECT - Maintenance
Role: lead
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
Role: lead
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
Role: lead
Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis
Role: lead
ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment
Role: lead
Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients
Role: lead
ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
Role: lead
ABX464 First in Man Study
Role: lead
A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults
Role: lead
Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
Role: lead
Safety and Pharmacokinetics Study in Healthy Japanese Volunteers
Role: lead
Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464
Role: lead
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Role: lead